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A murine model of early 
Pseudomonas aeruginosa lung 
disease with transition to chronic 
infection
H. K. Bayes, N. Ritchie, S. Irvine & T. J. Evans
Pseudomonas aeruginosa (PA) remains an important pathogen in patients with cystic fibrosis (CF) lung 
disease as well as non-CF bronchiectasis and chronic obstructive airways disease. Initial infections are 
cleared but chronic infection with mucoid strains ensues in the majority of CF patients and specific 
interventions to prevent this critical infection transition are lacking. The PA bead model has been 
widely used to study pulmonary P.aeruginosa infection but has limitations in animal husbandry and in 
accurately mimicking human disease. We have developed an adapted agar bead murine model using 
a clinical mucoid strain that demonstrates the key features of transition from transitory to chronic 
airways infection. Infected animals show very limited acute morbidity and mortality, but undergo 
infection-related weight loss and neutrophilic inflammation, development of anti-pseudomonal 
antibodies, variable bacterial clearance, endobronchial infection and microbial adaptation with PA 
small colony variants. We anticipate this model will allow research into the host and microbial factors 
governing this critical period in Pseudomonas aeruginosa pulmonary pathogenesis when transition to 
chronicity is occurring.
Pseudomonas aeruginosa (PA) remains an important pathogen in patients with cystic fibrosis (CF), as well as caus-
ing disease in non-CF bronchiectasis1 and chronic obstructive airways disease (COPD)2,3. Persistent PA infection 
also commonly complicates lung transplantation with associated poorer long-term outcome4,5. Persistent pul-
monary PA infection has been most widely studied in CF. Initially infections are cleared by host responses and 
anti-microbial therapy, but the majority of patients transition to chronic infection with biofilm-forming mucoid 
strains of PA that cannot be eradicated6. Persistent pulmonary infection is associated with a neutrophil-dominated 
host response, progressive respiratory function decline and reduced patient survival in CF7. Therefore a ‘window 
of opportunity’ exists to prevent transition to chronic infection. Current strategies can delay infection but inter-
ventions that truly prevent establishment of chronic PA infection, including anti-pseudomonal vaccines, have 
remained elusive8.
Lack of representative models of human lung disease due to PA infection has been a significant bar to research. 
Murine models of CF lung disease, with mutated CF transmembrane receptors (CFTR), fail to develop sponta-
neous and chronic PA infection9,10. Porcine and ferret models with mutant CFTR hold promise11,12 but remain 
in their infancy and lack of reagents, particularly in immunobiology, limit use. Administration of free-living 
Pseudomonas to the murine lung results in either rapid bacterial clearance or acute overwhelming sepsis9. To 
mimic persistent infection, PA must be inoculated within an immobilizing agent. Cash et al.13 originally described 
a model utilizing PA-laden agar beads in rats. Embedding PA within beads allows bacterial retention, protected 
from physical and immune elimination, so mimicking the bacterial biofilm seen within the lung in chronic 
infection.
The agar bead model is technically demanding, including requirement for surgical transtracheal instillation 
of bead suspension14. High procedure-related mortality rates exist with up to 45% intra-operative mortality 
reported14, although many studies fail to report such animal losses. The majority of studies utilize injectable 
anaesthesic agents.
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The agar bead model has predominantly been advocated as a mimic of established chronic Pseudomonas 
aeruginosa infection9,15. However the majority of studies utilize early time-points with a high level of acute 
inflammation and infection. Recently a model of chronic infection with established pulmonary epithelial degen-
eration, collagen deposition and elastin degradation has been described and more accurately represents estab-
lished lung disease15. At the time of writing, modeling the ‘window of opportunity’ where transition to chronic 
Pseudomonas aeruginosa infection is occurring has not been described. Following refinement of the surgical 
technique we describe our observations using a clinically relevant mucoid PA, strain NH57388A, to develop a 
model that is representative of the critical transition period where chronic infection is becoming established in 
the lungs of patients.
Materials and Methods
Ethical Statement. The animal studies were approved by the granting of a project license from the UK 
Home Office, a ministerial UK government department that oversees all experimental work with animals in the 
UK. The project license number is 60/4361. All housing, maintenance and experimentation on animals used 
in these studies is thus in accordance with and fully compliant with the UK Government “Animals (Scientific 
Procedures) Act 1986” as revised (2013) to incorporate European Directive 2010/63/EU on the protection of ani-
mals used for scientific purposes. This work was also reviewed and approved by the University of Glasgow Animal 
Welfare and Ethical Review Board, under the same license number.
Animals. C57BL-6 mice, aged 12–16 weeks old, were used (obtained from Harlan Laboratories and main-
tained at the University of Glasgow, UK).
PA-laden agar beads. Tryptic soya agar beads laden with PA were produced as described previously14. The 
mucoid PA strain NH57388A, derived from the sputum of a patient with CF, was utilized (kindly provided by 
N. Hoffmann, University of Copenhagen). NH57388A-laden agar beads were prepared the day before inoculation, 
stored overnight at 4 °C, suspended in sterile PBS to deliver approximately 1 × 106 CFU in 50 μ l per mouse. The 
inoculation dose was chosen following initial experiments demonstrating high acute mortality with higher inoc-
ulation doses. Different bead preparations were used for each experiment. Following PA-laden beads inoculation, 
the administrated inoculum was confirmed by quantitative bacteriology. Sterile agar beads were used for several 
experiments and confirmed as sterile before and after each use.
The model was developed and phenotyped in 82 mice; typically 10 mice per group used in a given experiment 
with 34 mice treated with sterile beads and 48 treated with NH57388A-laden agar beads. Ongoing work exam-
ining immune responses to PA infection (total 300 animals treated with both sterile and PA-laden agar beads) 
provided greater experience of true operative mortality.
Trans-tracheal instillation of beads. The technique for trans-tracheal instillation of beads is detailed in 
Fig. 1. Mice were anaesthetized with inhaled isoflurane delivered initially in an anaesthetic box until unconscious, 
transferred to a surgical board and maintained under anesthesia with isoflurane via nose cone (Fig. 1b). The 
ventral cervical region was sterilized and 1-cm midline skin incision made just cranial to the thoracic inlet. The 
trachea was visualized by blunt dissection (Fig. 1c). Traction on the lower jaw was used to extend and straighten 
the trachea and a 22G intravenous catheter (BD Biosciences) used to cannulate the trachea (Fig. 1d). A 1-ml 
syringe, pre-filled with beads suspended in PBS, was attached to the cannuale (Fig. 1e). The cannulae and syringe 
were left in-situ for 5-seconds following depression of the plunger, followed by slow withdrawal. The animal was 
elevated head up to 45-degrees (Fig. 1f). A rapid rise in respiratory rate was frequently observed at this point 
suggesting accurate intrapulmonary bead instillation. If evidence of respiratory distress (rapid or labored respira-
tion/gasping) occurred during the procedure anesthesia was rapidly reversed and oxygen alone administered via 
nose cone. The incision was closed with surgical staples (Fig. 1g,h). Buprenorphine analgesia (Vetergesic; Alstoe 
Animal Health) was administered subcutaneously post-operatively.
Post-operative care. Animals were monitored post-operatively in a heat box until ambulant and clinically 
normal. Mice were transferred to a clean box with food and water ad libitum and monitored at 1-hour, 4-hours 
and 8-hours post-operatively using a clinical scoring system for disease severity. Animals were weighed and 
scored clinically daily. Animals reaching a moribund end-point or with weight loss of greater than 20% of baseline 
weight were terminated prior to the pre-defined experiment end-point. Experiments were terminated at 2-weeks 
post-inoculation via carbon dioxide asphyxiation.
Blood, bronchoavlaeolar lavage (BAL), pulmonary lymph nodes and lung tissue were harvested from each 
animal under aseptic conditions. 1-ml of sterile phosphate buffered saline (PBS) infused and aspirated into the 
airways three times for each BAL sample. Thoracic lymph node cells were obtained from the bilateral mediastinal 
lymph nodes and single tracheobronchial lymph node16. The lung was divided based on given lobes for different 
outcome measures: right apical lobe for myeloperoxidase (MPO) assay, right diaphragmatic lobe for microbiol-
ogy, and left lung inflation fixed for histology in zinc fixative (BD Pharmingen).
Bacteriology. Lung tissue was mechanically homogenized in 1-ml PBS. Blood, BAL and lung homogenates 
were plated for quantitative bacteriology on Luria-Bertani (LB) agar (Invitrogen) and examined after 24 and 
48 hours incubation. Colonies were confirmed to be PA by appearance, Gram stain (BD Biosciences) and oxidase 
testing (Sigma-Aldrich). Smaller atypical colonies, known as PA small-colony variants (SCV)17,18, were confirmed 
as Pseudomonas species via VITEK2® identification. Chronic infection was defined as recovery of mucoid PA 
from lung cultures at 2-weeks post-inoculation.
For transmission electron microscopy (TEM), bacterial strains were grown on a coverslip in a petri-dish with 
LB broth at 37 °C for 36-hours. These were then washed in PBS, processed and stained as previously described19.
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Measurement of immunological parameters. Neutrophil quantification. Blood and BAL samples 
underwent red blood cell (RBC) lysis (Red cell lysis buffer; Sigma-Aldrich) prior to staining with Gr-1 (Ly6G; 
RB6-8C5; BioLegend) for flow cytometry (FACS Aria; BD Biosciences). MPO activity was quantified using a kit 
following the manufactuer’s instructions (Sigma-Aldrich).
Lymph node B cell quantification. Thoracic lymph nodes, passed through 80 μ m nitrex mesh, underwent RBC 
lysis, prior to staining with CD19 (6D5; BioLegend) and B220 (RA-6B2; BioLegend) for flow cytometry.
Figure 1. Technique for intra-tracheal instillation of agar beads using inhaled anaesthesia. (a) Sterile 
surgical equipment set-up required for instillation. (b) Following anesthesia administered via isofluorane 
inhalation in an anesthesia box, animals were transferred to the surgical board and maintained under 
anaesthesia via nose cone. (c) Midline neck incision and careful division of soft tissues to expose trachea.  
(d) Insertion of 22G intravenous cannula into trachea, while extending neck using traction on lower jaw.  
(e) Injection of 50 μ l of beads/PBS via cannula. (f) Elevation of anaesthetized animal on surgical board head-up 
to 45-degrees for a timed 1-minute in order to aid full inspiration of beads. (g) Closure of incision with surgical 
staples. (h) Completed closure of incision.
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Lung histology. Lungs were embedded in paraffin, sectioned at 5 μ m and stained with haematoxylin and eosin. 
Histology was scored for peribronchial and alveolar involvement using a scoring system adapted from Dubin et al.20  
(Table 1). Lung section scoring was performed at x10 magnification with an overall score given for whole lung 
sections and verified by independent blinded investigators.
PA-specific immunoglobulin quantification. At termination (2-weeks post-infection), blood was aspirated from 
the inferior vena cava, followed by centrifugation to obtain serum for immunoglobulin (Ig) quantification. 
ELISA-based detection of PA-specific IgM and IgG was utilized21 with binding bacterial protein derived from the 
NH57388A strain. Bound antibody was quantified by detection of biotinylated goat anti-mouse IgM (mu chain 
specific; VectorLabs) or anti-mouse IgG (Fc specifc; Sigma-Aldrich).
Statistical analysis. Results are presented as medians or, for technical repeats, mean and standard error of 
mean (SEM). Non-parametric Mann-Whitney or Kruskal-Wallis tests were used. Animal weight were compared 
repeated-measures ANOVA. Statistical analysis was undertaken using Prism Version 6.0 (GraphPad Software).
Results
Operative outcome. Prior to the use of trans-tracheal instillation of beads in our model, we undertook 
preliminary experiments to exploring alternative means of delivering the agar beads, namely cannulation of the 
trachea via the oral cavity and intranasal instillation, with the aim of effective bead delivery but reduced inci-
sion-related inflammation in the model. Experiments on mice cadavers with attempted cannulation of the trachea 
via the mouth demonstrated high levels of insertion outside of the tracheal, particularly gastric cannulation. 
Secondly, bead inoculation was attempted via intranasal inhalation in animals under an inhaled isoflurane anes-
thetic, with inoculated animals culled 1-hour later and lung sections stained and screened for presence of agar 
beads. This demonstrated very infrequent, small agar beads within the airways, suggesting either lodging of the 
beads within the upper airways or swallowing of beads. In contrast, frequent and larger beads that were identified 
in lung sections of mice administered beads via the trans-tracheal route. Thus the trans-tracheal route of instilla-
tion was subsequently utilized in our model.
The adapted intratracheal method (Fig. 1) demonstrated accurate delivery and retention of PA, 100% of 
lungs (N = 8) infected at 24-hours post-surgery. Animals recovered rapidly post-procedure; ambulant within 
10-minutes and clinically normal within 30-minutes. Overall extremely low intra-operative or early peri-operative 
(< 1 hour post-procedure) mortality rates resulted from the adapted transtracheal method: 4 fatalities in 300 pro-
cedures (operative mortality rate 1.3%). These deaths occurred during or shortly following completion of surgery.
Clinical effect of infection. The majority of mice remained clinically normal throughout. Post-procedure 
weight loss was significantly greater and sustained in animals developing chronic NH57388A pulmonary infec-
tion compared with sterile controls (Fig. 2a; p < 0.0001, via repeated measures ANOVA). Animals treated with 
PA-laden beads who cleared infection had early weight loss but returned to weights similar to sterile bead treated 
mice within 5-days (Fig. 2b).
Establishment of persistent infection. High acute mortality (> 1-hour post-procedure but before the 
2-week defined experimental endpoint) occurs in pseudomonas pneumonia22 but is not a feature of the transition 
to chronic pulmonary PA infection in the human population. Correspondingly limited acute mortality occurred 
in animals treated with NH57388A-laden beads (3 mice, 6% of total NH58773A-inoculated mice); culled due to 
weight loss > 20% of baseline and demonstrated high pulmonary bacterial burden (mean 3.6 × 109 CFU in lung 
homogenates, SD: 9.4 × 109 CFU). No acute mortality occurred in sterile bead treated mice.
Overall, NH57388A-laden bead inoculation resulted in mean chronic PA infection rates at 2-weeks of 37.3% 
(SD: 18.3%; range: 11.1–60%). Median pulmonary PA burden at 2-weeks was 1355 CFU (total of BAL and right 
diaphragmatic lobe homogenate; IQR: 182–2898). No P. aeruginosa was isolated from animals treated with sterile 
agar beads. No bacteria were isolated from terminal blood cultures of any animal.
Bacterial adaptation. Lung homogenates and BAL samples obtained from animals chronically infected 
with NH57388A demonstrated two distinct Pseudomonas aeruginosa colony morphologies: large mucoid colonies 
identical in morphology to the inoculating strain and smaller atypical small-colony variants (SCVs) (Fig. 2c–f). 
Small colony variants are very well described as part of the phenotypic adaptations to the CF lung23. Mucoid 
colonies were evident after 24-hours, whereas SCVs were only visible after 48-hours of incubation. TEM analysis 
Score Peribronchial infiltrate Alveolar involvement
0 None None
1 Mild (infiltrate ≤ 4 cells thick) Mild (patchy increased cellularity/thickening)
2 Moderate (infiltrate 5–10 cells thick) Moderate (25–50% visualized lung with increased cellularity/thickening)
3 Severe (25–50% visualized lumens) Severe (> 50% visualized lung with increased cellularity/thickening)
4 Diffuse (> 50% visualized lumens)
Table 1.  Histological scoring system for inflammation in lungs of mice treated with sterile agar beads and 
beads laden with Pseudomonas aeruginosa. Randomly selected sections blindly scored with a score applied to 
review of a whole lung section, scored at x10 magnification.
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Figure 2. Weight loss and bacterial adaptation in mice infected with NH57388A-laden agar beads.  
(a,b) Body weight measured daily in C57BL/6 mice treated with sterile or Pseudomonas aeruginosa-laden agar 
beads. Animals who were infected with NH57388A-laden beads and, at 2-weeks post-inoculation, remain 
infected are denoted as ‘Chronic infection’ (a), where as those who do not have pulmonary infection are 
denoted ‘Infection cleared’ (b). Percentage weight change from baseline for pooled experiments with animals 
treated with NH57388A-laden beads (N = 35) compared with controls treated with sterile beads (N = 30 mice). 
Each point represents mean of group and SEM. (a) Difference between groups significant at p < 0.0001 via 
repeated measures ANOVA. (b) Difference between groups significant at p = 0.0204 via repeated measures 
ANOVA. (c,d) Mucoid (white arrow) and small colony variants (black arrow) identified in lung homogenate of 
NH57388A-laden bead treated animal 2-weeks following inoculation. (e) Subcultures of mucoid NH75388A 
and small colony variant (SCV) phenotypes isolated from the lungs of animals treated with NH57388A-laden 
beads (grown on blood agar). (f) Transmission electron microscopy of biofilms of mucoid NH57388A and its 
small colony-variant. Mucoid NH57388A demonstrated low bacterial density with limited extracellular matrix. 
The related SCV produced a biofilm with a high density of highly adherent bacteria embedded in a dense 
network of extracellular material. Bacteria indicated by think white arrow and extracellular matrix by thin white 
arrow.
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of the SCV and its parent strain NH57388A demonstrated marked differences in biofilm formation (Fig. 2f). The 
biofilms of mucoid NH57388A demonstrated low bacterial density within the limited extracellular matrix. In 
contrast, the related SCV produced a biofilm with a high density of highly adherent bacteria embedded in a dense 
network of extracellular material (Fig. 2f). This complex and adherent biofilm is likely a key factor in the ability 
of SCVs to produce lung pathology.
Overall SCVs were present in 12 of 17 animals (70.6%) with chronic NH57388A infection. To ascertain that 
the SCV development was not due to embedding in beads alone, NH57388A-beads were cultured intact and 
homogenized between 24-hours to 2-weeks after bead formation with no evidence of SCV development, repeated 
for 3 separately produced bead batches. In addition, culture of NH57388A from stock demonstrated only mucoid 
morphology even with prolonged culture. Thus in vitro pressures and environment within the model appear to 
be required for SCV development.
Neutrophilic inflammation. Neutrophil inflammation is consistently implicated in CF lung disease com-
plicated by chronic PA infection where such neutrophilic responses fail to clear the organism but contribute to 
host damage24. Pediatric CF studies have demonstrated elevation of pulmonary inflammatory markers only in 
the presence of infection25. In keeping with these clinical observations, high levels of pulmonary neutrophilic 
inflammation were seen 48-hours following inoculation of NH57388A-laden agar beads (median BAL neu-
trophils (percent of total leukocytes) 79.9% (IQR: 57.3–90.2)) compared with sterile bead controls at the same 
time-point (median BAL neutrophils 1.76% (IQR: 0.84–6.84)). Importantly, pulmonary neutrophilic inflamma-
tion persisted at two-weeks post-inoculation with PA infection (Fig. 3a). Inflammation returned towards normal 
once infection cleared; median BAL neutrophils in chronically infected animals being 5.01% of total leukocytes 
compared with 0.68% in animals clearing PA prior to 2-weeks (p = 0.0010 via Mann-Whitney test). There was no 
significant increase in total lung tissue MPO activity in PA infected animals compared with sterile controls (data 
not shown). Peripheral blood neutrophils were similarly not significantly elevated at 2-weeks post-inoculation 
with PA-laden beads compared with sterile controls (data not shown), consistent with confined intrapulmonary 
sepsis and inflammation.
Intra-pulmonary immune response. Persistent pulmonary inflammatory changes were evident 2-weeks 
post-inoculation with higher histological scoring in PA treated animals (Fig. 3b). A range of histological scores 
was seen in infected animals, likely reflecting the localized histological changes at sites of infection and random 
sampling of these. Minimal changes were seen in response to agar bead instillation per se (Fig. 3d). Infected lungs 
demonstrated localized peribronchial monocytic infiltrates with an agar bead frequently evident in the adjacent 
airway (Fig. 3e). This localized infiltrate was in contrast to the intense parenchymal inflammation seen in animals 
succumbing acutely with high bacterial burden (Fig. 3f).
Systemic anti-pseudomonal immunoglobulin production. NH57388A infection resulted in macro-
scopic pulmonary lymph nodes enlargement at 2-weeks post-inoculation, confirmed quantitatively on cell counts 
(Fig. 3g). Pseudomonas aeruginosa-specific immunoglobulins (Ig) are produced by CF patients and levels have 
been found to increase progressively as chronic PA infection develops26,27. Serum PA-binding immunoglobulins 
significantly increased 2-weeks post-inoculation of NH57388A, with a median fold increase in PA-binding IgM of 
1.162 (IQR: 0.994–1.362) and IgG of 1.334 (IQR: 1.101–2.521) compared with sera of sterile bead treated animals 
(p < 0.0001 for both, compared with theoretical median of 1.0 via Wilcoxon signed rank test) (Fig. 3h).
Discussion
Developing models akin to human disease is essential to any research field but has remained problematic in 
cystic fibrosis pulmonary disease. The agar bead model has been advocated as reproducing the lung pathology of 
patients with CF with advanced and established chronic pulmonary infection9,14. However, the NH57388A-laden 
agar bead model described in this paper has features akin to the critical stage in CF lung disease when there is 
non-resolution of mucoid Pseudomonas aeruginosa infection and transition to chronic infection occurs. Our 
murine model demonstrated clinical, immunological and microbiological features mirroring that of human 
lung disease seen with the development of persistent PA infection: low levels of morbidity, weight loss related 
to infection, endobronchial neutrophilic inflammation and infection, adaptive immunity with production of 
pseudomonas-binding Ig, variable clearance of a clinical mucoid PA strain and microbial adaptation12,17,24,26,28.
Progression of lung disease in CF with irreversible changes and bacterial colonization is usually insidious. 
Our described model does not attempt to reflect CF lung disease from its onset as multiple additional infective, 
including infection with Staph. aureus, and inflammatory insults beginning early in life and precede PA infection. 
However, we demonstrate non-resolution of mucoid PA in a clinical relevant strain. Overwhelming sepsis is not a 
typical feature of early PA infections and thus, importantly, aggressive infection and acute mortality was limited in 
our described model. However, patients frequently manifest poor growth and nutritional status has increasingly 
been recognized as an important determinant of pulmonary health and survival29. CF-related pancreatic disease 
contributes but pulmonary PA infection and the associated inflammation also drives nutritional failure30. Our 
model demonstrated significant weight loss in relation to infection, which peaked acutely but remained sustained 
at least 10-days post-infection (Fig. 2a), with the potential to investigate interventions against this important 
cause of patient morbidity.
Neutrophilic inflammation in response to persistent Pseudomonas aeruginosa infection has been consistently 
implicated in pathogenesis of CF24,25. Indeed sustained endobronchial neutrophilic inflammation was evident 
(Fig. 3a). The fact that there was no increase in whole lobe MPO in our model would be consistent with inflam-
mation predominantly confined to intra/peri-bronchial regions rather than inducing a significant parenchymal/
pneumonia-like infection. The role of B and T lymphocyte immunity in anti-Pseudomonal immunity has not 
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Figure 3. Neutrophilic inflammation, histological changes and Pseudomonas-binding immunoglobulin 
in mice two-weeks following NH57388A-laden agar bead inoculation. C57BL/6 mice received sterile or 
NH57388A-laden agar beads. (a) Two-weeks post-instillation, bronchoalveolar lavage (BAL) leukocytes were 
strained for Gr-1 followed by flow cytometry. BAL neutrophils (percent of total leukocytes) in animals treated 
with sterile beads (N = 16) were compared mice inoculated with NH57388A-laden agar beads (N = 19) at 
2-weeks. Line indicates median. P-value related to Mann-Whitney test. (b) Quantitative histological scores of 
animals treated with sterile agar beads (N = 9) or NH57388A (NH)-laden beads (N = 9). Line denotes median 
score. P-value related to Mann-Whitney test. (c–f) H&E staining of representative lung sections (all at x10 
magnification) in C57BL/6 mice with no treatment (healthy control) (c), 2-weeks post-inoculation with sterile 
agar beads (d), 2-weeks post-inoculation with NH57388A-laden agar beads (e), or with overwhelming acute 
infection post-inoculation with PA-laden agar beads. Black arrows highlight intra-bronchial agar beads.  
(g) Mediastinal lymph node cell counts in mice treated with sterile and PA-laden agar beads two-weeks 
following bead instillation. Columns shown mean + SD. P-value relates to comparison by t-test and includes 
results from 3 experiments (each with N = 9–10 mice/group). (h) Serum PA-binding immunoglobulin M (IgM) 
and G (IgG) levels showing fold increase in IgM and IgG levels in NH57388A treated animals compared with 
sterile bead treated controls two-weeks post-instillation. Line represents median. *Denotes p < 0.05 compared 
with theoretical median of 1.0 via Wilcoxon Signed rank test. Combined results from two separate experiments.
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been well-characterized to-date. We found significant regional lymph node enlargement (Fig. 3g) and systemic 
anti-pseudomonal antibody (Fig. 3h) consistent with lymphocytic recruitment and adaptive immune activation. 
We have subsequently utilized the model to interrogate the role of inflammatory cytokine responses in protecting 
against chronic infection31 and defining novel cytokine-producing B cells recruited during infection (manuscript 
submitted, Bayes et al.). Further work may utilize such B cell responses for novel anti-pseudomonal mucosal 
vaccination approaches32.
The described model was developed in C57Bl6 mice rather than CFTR mutant animals, which makes the 
model of utility to non-CF related disease. Recent comparison of the agar bead model in a more chronic infec-
tion than described in our manuscript, demonstrated that persistent immune responses and airway remode-
ling were similar in CFTR mutant versus wild-type controls15. Whether the period of transition to chronicity is 
however adversely effected by exacerbated inflammatory responses or defective PA clearance requires further 
interrogation.
Others have previously utilized clinical CF strains of PA in agar bead model33. We utilised the clinical 
P. aeruginosa NH57388A strain which has a mutation in mucA resulting in alginate hyper-production34; relevant 
as alterations in mucA are the most frequently identified mutations in mucoid Pseudomonas isolates from CF 
patients35. NH57388A has previously been embedded in alginate in CF and BALB/c mice34, yet this alternate 
model resulted in significant acute mortality and limited evidence provided to suggest persistent infection beyond 
7-days. Embedding NH57388A in agar beads prevented significant acute mortality, produced chronic infection 
rates of approximately 40% and pulmonary bacterial burden comparable to that achieved by others utilizing 
alternative PA strains9,36.
To mimic human disease, experimentally instilled P. aeruginosa should proliferate and adapt within the lung. 
The high bacterial burden in animals succumbing acutely and the development of small-colony variants confirms 
that PA has actively proliferated and adapted in vivo. Development of SCVs is particularly relevant to human 
CF disease23. Over 2-year follow-up, P. aeruginosa SCVs were isolated from 38% of adult CF patients infected 
with the organism and associated with poorer lung function and increased antibiotic usage37. Functionally, PA 
SCVs demonstrate features favoring persistent infection including increased biofilm formation17,38, adherence17, 
macrophage cytotoxity38, and antibiotic resistance37. These factors would suggested an ability of SCVs to evade 
host responses rather than showing increased virulence per se. We found no evidence of systemic spread of PA 
including in animals with intrapulmonary PA SCVs. Whether PA SCVs demonstrate increased virulence could 
be further examined in the model by infection with PA SCVs embedded in agar beads compared infection with 
the mucoid parent strain from the onset. Thus the described model opens up exciting opportunities to explore 
the genetic and environmental determinants of SCV development and investigate therapeutic targeting of this 
PA subtype.
Although Pseudomonas aeruginosa is commonly identified as a CF pathogen, the organism complicates 
and adversely effects outcome in the broader respiratory population. In non-CF bronchiectasis and chronic 
obstructive airways disease (COPD) persistent infection is associated with more rapid decline in lung function, 
anti-pseudomonal antibody formation as well as the PA isolates demonstrating features seen in CF disease with 
mucoid phenotype, increased antibiotic resistance and biofilm formation1–3. Persistent PA infection in allograft 
lungs has been consistent identified as a risk factor for chronic rejection, namely bronchiolitis obliterans syn-
drome4,5. Thus our described modeling transition to chronic pulmonary PA infection has utility in wider respira-
tory disease.
Improvements in laboratory animal welfare remain of paramount importance in disease model development. 
To this end we describe in detail our method for using inhaled anesthesia to allow transtracheal intubation of 
mice, with the advantages of reliable and easily reversible sedation if respiratory compromise develops during the 
procedure and rapid post-operative recovery. Despite use by previous authors, we are unaware of this technique 
being described in detail to-date that allows replication nor to demonstrate the potential benefits on operative 
mortality. Resultant intra-/perioperative mortality was extremely low (overall 1.3%) in our model, significantly 
lower than previously reported using injectable agents14. Although operative outcome is dependent on user expe-
rience and skill14, the low procedure-related mortality was consistent throughout our use of the model (i.e. was 
not related to mounting experience in the technique; data not shown). Organism virulence also effects outcome33 
but would not be relevant to outcome described here given that we found the majority of peri-operative deaths 
occurred during/very close to the time of procedure. Importantly the model adaptions are in concordance with 
the principle of “refinement” in animal research both by improving operative outcome and by describing clear 
features akin to human disease.
A limitation of the model is in mimicking established CF lung disease with the associated structural changes 
of mucus plugging, gas trapping and bronchiectasis. Although the NH57388A-agar bead model demonstrated 
greater histological changes compared with sterile bead controls, this was limited to peribronchial monocytic 
infiltrates (Fig. 3). However arguably it is not possible to replicate in short-lived murine models a process that, in 
man, requires years of multiple infective and inflammatory insults to develop. Thus our approach to mimicking 
the transition period to chronic colonization in the CF lung appears more realistic. The stability of infection 
beyond 2-weeks was not examined, although others have demonstrated static bacterial burden beyond 2-weeks 
using alternate murine agar bead models9.
Pseudomonas aeruginosa remains an important respiratory pathogen, particularly in its ability to evade host 
and therapeutic strategies to establish chronic infection. The described NH57388A-agar bead model will allow 
interrogation of the microbiology and immune mechanisms during the critical ‘window of opportunity’ prior to 
established chronic Pseudomonas infection.
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